A new weapon has been added to the global fight against the epidemic.
The recombinant novel coronavirus vaccine (CHO cell), jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifielong Koma Biopharmaceutical Co., Ltd., has been approved for emergency use in China, becoming the fifth novel coronavirus vaccine approved for emergency use in China. At present, the vaccine has been officially approved on the market in Uzbekistan, which is the first novel coronavirus recombinant subunit protein vaccine approved for clinical use in the world. The vaccine has independent intellectual property rights.
It is understood that China is currently carrying out the urgent development of the new coronavirus vaccine according to five technical routes: inactivated vaccine, adenovirus vector vaccine, nucleic acid vaccine, recombinant protein vaccine and attenuated influenza virus vector vaccine. The vaccine developed by Anhui ZhiFeilong Koma Biopharmaceutical Co., Ltd. adopts the recombinant protein vaccine technology, which is to prepare the antigen of the receptor binding region of Novel Coronaviruss protein expressed by recombinant engineered cells into the vaccine, without involving the production process of the complete virus. Vaccines stimulate the body to produce antibodies, creating immunity.
The restructuring of the new vaccine has significant advantages, completed Ⅰ, Ⅱ period and ongoing Ⅲ phase of clinical trial, showed that the vaccine has good safety and immunogenicity. Ⅰ phase of clinical trial Yang turn rate is 100%, and 94.5, the antibody concentration Ⅱ phase of clinical trial Yang turn rate is 96.6%, and 102.5 antibody concentration. In vitro neutralization test results showed that the vaccine still had protective effect against the South African strain (501Y.V2).
The new corona-specific antigen was produced by gene recombination technology with advanced technology, good safety and controllable quality. There is no biosafety risk in vaccine production, and the antigen is cultured in a large-capacity bioreactor (1000 liters), which is mature and stable, and easy to be produced on a large scale.
Reporters have learned that the vaccine needs to be vaccinated with three injections, and the current production capacity of Chi Flyong Coloma is 300 million doses, which is equivalent to meeting the needs of 100 million people. The company is also actively promoting the expansion of production capacity, six production lines are under construction, after reaching the production capacity can be increased to about 900 million, to meet the needs of about 300 million people every year for vaccination.
Reprint indicated source：Spark Global Limited information